Phase 2
Completed N=140
Topiramate for the Treatment of Methamphetamine Dependence - 1
Methamphetamine
Source: ClinicalTrials.gov NCT00345371 ↗
Enrolled (actual)
140
Serious AEs
7.9%
Results posted
Feb 2017
Primary outcomePrimary: Abstinence (Weeks 6 - 12) — 49; 49; 43; 48 Participants
Summary
The purpose of this study is to assess the efficacy and safety of topiramate as compared to placebo in reducing methamphetamine use in subjects with methamphetamine dependence.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Abstinence (Weeks 6 - 12) |
49; 49; 43; 48; 46; 45 | — |
| SECONDARY Abstinence (Weeks 1 - 12) |
58; 53; 56; 50; 55; 50 | — |
Eligibility Criteria
Inclusion Criteria
- Treatment seeking individuals as the time of the study
- Must be able to proved written informed consent
- Must have a body mass index greater than 18 kg/m(2)
- Must meet DSM-IV criteria for methamphetamine dependence
- Must currently be using methamphetamine as confirmed by a positive urine test over the past 14 days
- If female of child bearing potential, must agree to use birth control
Exclusion Criteria
- Please contact the site for more information
Data sourced from ClinicalTrials.gov (NCT00345371). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.